BOCA RATON, Fla. — August 7, 2025 — Leads & Copy — INmune Bio Inc. (NASDAQ: INMB) has announced its financial results for the quarter ended June 30, 2025, alongside a business update. The clinical-stage immunology company is focused on developing treatments harnessing the patient’s innate immune system to combat disease.
Key highlights from Q2 2025 and recent activities include:
DN-TNF Platform (XPro™): Top-line data from the MINDFuL phase 2 trial, involving 208 patients with MCI and early Alzheimer’s, was released. While the trial did not meet its primary cognitive endpoints in the 200 modified mITT patients, XPro™ showed a positive impact on the primary cognitive endpoint EMACC in a pre-defined subset of 100 patients (50%) with two or more biomarkers of inflammation. Additional data was presented at the Alzheimer’s Association International Conference (AAIC) on July 29th by Dr. Sharon Cohen of the Toronto Memory Program.
CORDStrom™ Platform: A favorable written opinion was received from the USPTO on all claims in INmune Bio’s international patent application PCT/US25/17028. The company partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish commercial-ready manufacturing for CORDStrom™ and other cell therapy platforms. The complete database of clinical data from the trial of CORDStrom™ in Recessive Dystrophic Epidermolysis Bullosa (RDEB) has been delivered to an independent statistical analysis company.
INKmune® Platform: Following the success in meeting the primary endpoint at completion of the phase I aspect of the CARE-PC trial, phase II was initiated in Q1, quickly enrolling the first three patients. Early analysis of blood samples demonstrated that both secondary endpoints of NK activation and NK cell proliferation in vivo had been met. The CARE-PC trial has been closed to further recruitment to ensure completion of follow-up by the end of Q4 of 2025 as planned.
Corporate Updates: Dr. RJ Tesi has retired as CEO. David Moss has been appointed President & CEO and to the Board of Directors. Cory Ellspermann has been appointed as Interim CFO, and Kelly Ganjei as Chairman of the Board. The company closed a $19 million registered direct offering.
Upcoming Events and Milestones include an end-of-phase 2 meeting with the FDA regarding the MINDFuL trial, expected in the fourth quarter. The company will file a publication on the MINDFuL trial results this month and remains on track to file a Marketing Authorization Application (MAA) in the UK and Biologic License Application (BLA) for CORDStrom™ in RDEB by mid-2026.
Financial Results: Net loss attributable to common stockholders for the quarter ended June 30, 2025, was approximately $24.5 million, compared to $9.7 million in 2024. Research and development expenses totaled approximately $5.8 million, compared to $7.1 million in 2024. As of June 30, 2025, the Company had cash and cash equivalents of approximately $33.4 million.
David Moss
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
Source: INmune Bio Inc.
